AAUM (Average Assets Under Management) of ₹22.09 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 77.1% | 78.1% | ▲ +1.0% |
| Healthcare Services | 22.5% | 21.5% | ▼ -1.0% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% | ● 0.0% |
| N.A. | 0.0% | 0.0% | ● +0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.1% | 78.4% | ▲ +0.3% |
| Healthcare Services | 21.5% | 21.1% | ▼ -0.4% |
| Healthcare Equipment & Supplies | 0.5% | 0.4% | ● -0.1% |
| N.A. | 0.0% | 0.0% | ● 0.0% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Weight (Oct 2026) |
|---|---|---|---|
| 1 | Manipal Health Enterprises Ltd ₹7.02 L |
Healthcare Services | 0.33% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Laurus Labs Limited ₹1.24 Cr |
Pharmaceuticals & Biotechnology | 4.85% | 5.81% | +0.96% |
| 2 | Dr. Reddy's Laboratories Limited ₹1.09 Cr |
Pharmaceuticals & Biotechnology | 4.74% | 5.14% | +0.40% |
| 3 | Divi's Laboratories Limited ₹1.65 Cr |
Pharmaceuticals & Biotechnology | 7.44% | 7.73% | +0.29% |
| 4 | Acutaas Chemicals Ltd ₹27.46 L |
Pharmaceuticals & Biotechnology | 1.06% | 1.29% | +0.23% |
| 5 | Apollo Hospitals Enterprise Limited ₹1.14 Cr |
Healthcare Services | 5.23% | 5.36% | +0.13% |
| 6 | Piramal Pharma Limited ₹19.89 L |
Pharmaceuticals & Biotechnology | 0.81% | 0.93% | +0.12% |
| 7 | Zydus Lifesciences Limited ₹41.25 L |
Pharmaceuticals & Biotechnology | 1.83% | 1.94% | +0.11% |
| 8 | Cipla Limited ₹1.04 Cr |
Pharmaceuticals & Biotechnology | 4.80% | 4.88% | +0.08% |
| 9 | Gland Pharma Limited ₹32.62 L |
Pharmaceuticals & Biotechnology | 1.45% | 1.53% | +0.08% |
| 10 | Syngene International Limited ₹10.16 L |
Healthcare Services | 0.44% | 0.48% | +0.04% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited ₹2.55 Cr |
Pharmaceuticals & Biotechnology | 12.36% | 11.99% | -0.37% |
| 2 | Max Healthcare Institute Limited ₹84.60 L |
Healthcare Services | 4.33% | 3.97% | -0.36% |
| 3 | Torrent Pharmaceuticals Limited ₹72.68 L |
Pharmaceuticals & Biotechnology | 3.56% | 3.41% | -0.15% |
| 4 | Wockhardt Limited ₹20.90 L |
Pharmaceuticals & Biotechnology | 1.10% | 0.98% | -0.12% |
| 5 | Neuland Laboratories Limited ₹22.46 L |
Pharmaceuticals & Biotechnology | 1.16% | 1.05% | -0.11% |
| 6 | Biocon Limited ₹32.81 L |
Pharmaceuticals & Biotechnology | 1.64% | 1.54% | -0.10% |
| 7 | Krishna Institute Of Medical Sciences Limited ₹24.70 L |
Healthcare Services | 1.25% | 1.16% | -0.09% |
| 8 | GlaxoSmithKline Pharmaceuticals Limited ₹13.44 L |
Pharmaceuticals & Biotechnology | 0.71% | 0.63% | -0.08% |
| 9 | Lupin Limited ₹64.75 L |
Pharmaceuticals & Biotechnology | 3.11% | 3.04% | -0.07% |
| 10 | Shilpa Medicare Ltd ₹14.90 L |
Pharmaceuticals & Biotechnology | 0.77% | 0.70% | -0.07% |
139 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹2.55 Cr |
Pharmaceuticals & Biotechnology |
11.99%
|
|
| 2 |
₹1.65 Cr |
Pharmaceuticals & Biotechnology |
7.73%
|
|
| 3 |
₹1.24 Cr |
Pharmaceuticals & Biotechnology |
5.81%
|
|
| 4 |
₹1.14 Cr |
Healthcare Services |
5.36%
|
|
| 5 |
₹1.09 Cr |
Pharmaceuticals & Biotechnology |
5.14%
|
|
| 6 |
₹1.04 Cr |
Pharmaceuticals & Biotechnology |
4.88%
|
|
| 7 |
₹84.60 L |
Healthcare Services |
3.97%
|
|
| 8 |
₹72.68 L |
Pharmaceuticals & Biotechnology |
3.41%
|
|
| 9 |
₹64.75 L |
Pharmaceuticals & Biotechnology |
3.04%
|
|
| 10 |
₹61.63 L |
Pharmaceuticals & Biotechnology |
2.89%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.